budesonide/formoterol (PT009) / AstraZeneca 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
budesonide/formoterol (PT009) / AstraZeneca
VATHOS, NCT05202262 / 2021-002026-24: A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma

Active, not recruiting
3
645
Europe, Canada, Japan, US, RoW
BFF MDI 320/9.6 μg, BFF, BFF MDI 160/9.6 μg, BD MDI 320 μg, BD, Open-label Symbicort TBH 320/9 μg, Symbicort TBH
AstraZeneca
Asthma
02/25
02/25
LITHOS, NCT05755906 / 2021-003334-36: A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma

Active, not recruiting
3
374
Canada, US, RoW
BFF MDI 160/9.6 μg BID (320/19.2μg/day), BFF, BD MDI 160 μg BID (320 μg/day), BD
AstraZeneca, AstraZeneca AB
Asthma
11/24
11/24
KALOS, NCT04609878 / 2020-001520-34: Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma

Active, not recruiting
3
2212
Europe, Canada, Japan, US, RoW
BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort®
AstraZeneca, AstraZeneca AB
Asthma
03/25
03/25
LOGOS, NCT04609904 / 2020-001521-31: Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma

Active, not recruiting
3
2178
Europe, US, RoW
BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort®
AstraZeneca
Asthma
03/25
03/25
ATHLOS, NCT06067828: A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Recruiting
3
180
Europe, Canada, US, RoW
Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease
08/25
08/25

Download Options